本文選題：亞甲基四氫葉酸還原酶　切入點(diǎn)：基因多態(tài)性　出處：《中國藥學(xué)雜志》2017年18期 　論文類型：期刊論文

【摘要】：目的研究亞甲基四氫葉酸還原酶基因(MTHFR)C677T多態(tài)性與大腸癌術(shù)后患者接受卡培他濱聯(lián)合奧沙利鉑(XELOX)方案輔助化療療效的關(guān)系。方法對行大腸癌根治術(shù)后接受XELOX方案化療的62例患者,采用競爭性等位基因特異性聚合酶鏈?zhǔn)椒磻?yīng)(KASP)法檢測MTHFR C677T基因多態(tài)性并分析其與預(yù)后及不良反應(yīng)相關(guān)性。結(jié)果 62例結(jié)直腸癌患者的MTHFR C677T位點(diǎn)存在3種等位基因型,其基因頻率分別為:C/C 46.8%,C/T 40.3%,T/T 12.9%。C/T及T/T型患者無復(fù)發(fā)生存時(shí)間較C/C型延長(Log-rank=4.778,P0,05)。其中C/C型患者復(fù)發(fā)率為58.6%,顯著高于T/T及C/T基因型患者的33.3%(χ~2=3.985,P0.05)。TNM分期(HR=5.326,P0,05)及MTHFR C677T基因多態(tài)性(HR=0.284,P0.05)是術(shù)后輔助化療預(yù)后的影響因素。化療毒副反應(yīng)中以胃腸道反應(yīng)和骨髓抑制為主,但不同基因型之間差異并不具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論 MTHFR C677T基因多態(tài)性與XELOX方案輔助化療預(yù)后相關(guān)。TNM分期(Ⅳ期)術(shù)后輔助化療預(yù)后差。MTHFR C677T基因多態(tài)性與化療引起的毒副反應(yīng)無關(guān)。
[Abstract]:Objective to study the relationship between methylenetetrahydrofolate reductase gene MTHFRnC677T polymorphism and adjuvant chemotherapy efficacy of capecitabine combined with oxaliplatin XELOX regimen in patients with colorectal cancer. Methods 62 patients with colorectal cancer received XELOX regimen chemotherapy after radical resection of colorectal cancer. The polymorphism of MTHFR C677T gene was detected by competitive allele-specific polymerase chain reaction (KASP) method and its relationship with prognosis and adverse reactions was analyzed. Results there were three alleles at MTHFR C677T locus in 62 patients with colorectal cancer. The gene frequencies of C / C / C 46.8and T / T 40.30.3and T / T 12.9.Cr / T and T / T respectively prolong the recurrence survival time of patients with type C / C, and the recurrence rate of patients with C / C type is 58.60.It is significantly higher than that of patients with T / T and CT genotypes (蠂 ~ (33.3.985P0.05). TNM staging HR5.326P0O) and MTHFR C677T gene polymorphism HR0.284P0.05). The main adverse effects of adjuvant chemotherapy were gastrointestinal reaction and bone marrow suppression. Conclusion the polymorphism of MTHFR C677T gene is related to the prognosis of adjuvant chemotherapy of XELOX regimen. The prognosis of adjuvant chemotherapy is poor after the operation of stage 鈪，

本文編號：1637572